Literature DB >> 22892823

Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy.

M Wittstock1, I Pohley, U Walter, A Grossmann, R Benecke, A Wolters.   

Abstract

Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian syndrome and an important differential diagnosis of parkinson's disease (PD). The clinical diagnosis of PSP relies on characteristic symptoms. There is evidence of clinical subgroups within the entity of PSP interfering with making the firm diagnosis. It was the aim of the study to clarify the differences between phenotypical subtypes of PSP and PD focusing on transcallosal inhibition (TI). A systematic chart review of 67 patients supposed to have probable PSP was done in a standardized diagnostic work-up. As only complete data sets were included into further analysis, 26 PSP patients (mean age 68.6 ± 7.1 years) could be evaluated and subdivided into Richardson's syndrome (RS) (n = 15) or PSP of parkinsonian type (PSP-P) (n = 11). Fifteen PD patients served as controls. TI was evaluated by investigation of the ipsilateral silent period (iSP) with transcranial magnetic stimulation (TMS). Cognition was assessed by the Addenbrooke's cognitive examination (ACE-R). TMS revealed a significantly more severe affection of TI in RS patients as compared to PSP-P and PD patients who showed similar neurophysiological findings. 47 % of RS patient displayed an iSP loss, whereas PSP-P and PD did not. There was a significant correlation between iSP latency and ACE-R (Spearman's coefficient -0.369, P = 0.010). In conclusion, RS patients-contrary to PSP-P and PD patients-had pathological TI at least in one hemisphere indicating more severe involvement of transcallosally projecting output neurons in RS.

Entities:  

Mesh:

Year:  2012        PMID: 22892823     DOI: 10.1007/s00702-012-0879-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  36 in total

1.  Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy.

Authors:  M Warmuth-Metz; M Naumann; I Csoti; L Solymosi
Journal:  Arch Neurol       Date:  2001-07

2.  Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation.

Authors:  U Ziemann; D Bruns; W Paulus
Journal:  Neurosci Lett       Date:  1996-04-26       Impact factor: 3.046

3.  Clinical correlates of white matter tract degeneration in progressive supranuclear palsy.

Authors:  Jennifer L Whitwell; Ankit V Master; Ramesh Avula; Kejal Kantarci; Scott D Eggers; Heidi A Edmonson; Clifford R Jack; Keith A Josephs
Journal:  Arch Neurol       Date:  2011-06

Review 4.  Repetitive transcranial magnetic stimulation: a tool for human cerebellar plasticity.

Authors:  Giacomo Koch
Journal:  Funct Neurol       Date:  2010 Jul-Sep

5.  Cerebellar dysfunction in progressive supranuclear palsy: a transcranial magnetic stimulation study.

Authors:  Yuichiro Shirota; Masashi Hamada; Ritsuko Hanajima; Yasuo Terao; Hideyuki Matsumoto; Shinya Ohminami; Shoji Tsuji; Yoshikazu Ugawa
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

6.  Transcallosal inhibition in amyotrophic lateral sclerosis.

Authors:  M Wittstock; A Wolters; R Benecke
Journal:  Clin Neurophysiol       Date:  2006-11-30       Impact factor: 3.708

7.  Non-fluent progressive aphasia, depression, and OCD in a woman with progressive supranuclear palsy: neuroanatomical and neuropathological correlations.

Authors:  Niranjan S Karnik; Massimo D'Apuzzo; Michael Greicius
Journal:  Neurocase       Date:  2006-12       Impact factor: 0.881

8.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

9.  Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study.

Authors:  Raffaele Nardone; Igor Florio; Piergiorgio Lochner; Frediano Tezzon
Journal:  Exp Brain Res       Date:  2005-03-08       Impact factor: 1.972

Review 10.  Update on progressive supranuclear palsy.

Authors:  Irene Litvan
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

View more
  5 in total

Review 1.  Physiological changes in neurodegeneration - mechanistic insights and clinical utility.

Authors:  Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2018-03-23       Impact factor: 42.937

Review 2.  Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease.

Authors:  Steve Vucic; Matthew C Kiernan
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinson's Disease and Progressive Supranuclear Palsy.

Authors:  Francesco Fisicaro; Giuseppe Lanza; Mariagiovanna Cantone; Raffaele Ferri; Giovanni Pennisi; Alessandra Nicoletti; Mario Zappia; Rita Bella; Manuela Pennisi
Journal:  J Pers Med       Date:  2020-12-12

4.  The ipsilateral silent period: an early diagnostic marker of callosal disconnection in ALS.

Authors:  Annemarie Hübers; Jan Kassubek; Hans-Peter Müller; Nicolas Broc; Jens Dreyhaupt; Albert C Ludolph
Journal:  Ther Adv Chronic Dis       Date:  2021-09-13       Impact factor: 5.091

Review 5.  Clinical neurophysiology of Parkinson's disease and parkinsonism.

Authors:  Robert Chen; Alfredo Berardelli; Amitabh Bhattacharya; Matteo Bologna; Kai-Hsiang Stanley Chen; Alfonso Fasano; Rick C Helmich; William D Hutchison; Nitish Kamble; Andrea A Kühn; Antonella Macerollo; Wolf-Julian Neumann; Pramod Kumar Pal; Giulia Paparella; Antonio Suppa; Kaviraja Udupa
Journal:  Clin Neurophysiol Pract       Date:  2022-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.